Ultrapetrol Limited (ULTR) Drops 44.77% on January 01

Equities Staff |

Ultrapetrol Limited (ULTR) was one of the Russell 2000's biggest losers for Friday January 01 as the stock slid 44.77% to $0.11, a loss of $-0.0851 per share. Starting at an opening price of $0.20 a share, the stock traded between $0.10 and $0.20 over the course of the trading day. Volume was 2.21 million shares over 745 trades, against an average daily volume of 91,287 shares and a total float of 140.73 million.

The losses send Ultrapetrol Limited down to a market cap of $14.78 million. In the last year, Ultrapetrol Limited has traded between $2.20 and $0.10, and its 50-day SMA is currently $0.37 and 200-day SMA is $0.82.

Ultrapetrol (Bahamas) Ltd is a shipping transportation company serving the marine transportation needs of clients in the geographic markets for containers, grain soybean, forest products, minerals, crude oil, petroleum, and refined petroleum products.

Ultrapetrol Limited is based out of Nassau, and has some 1,614 employees. Its CEO is Damian Scokin.

For a complete fundamental analysis analysis of Ultrapetrol Limited, check out Equities.com’s Stock Valuation Analysis report for ULTR. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Trustify provides trust and safety in both the digital and physical worlds through our vast network of on-demand Private Investigators.By removing the large retainers and high hourly rates that traditional…


D-Wave Systems is the first quantum computing company. Its mission is to integrate new discoveries in physics, engineering, manufacturing, and computer science into breakthrough approaches to computation to help solve…